Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) EBT (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed EBT for 9 consecutive years, with $86.1 million as the latest value for Q4 2025.

  • Quarterly EBT fell 35.61% to $86.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $476000.0 through Dec 2025, down 99.83% year-over-year, with the annual reading at $476000.0 for FY2025, 99.83% down from the prior year.
  • EBT hit $86.1 million in Q4 2025 for Protagonist Therapeutics, up from -$39.3 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $210.7 million in Q1 2024 to a low of -$41.0 million in Q2 2022.
  • Historically, EBT has averaged $3.7 million across 5 years, with a median of -$31.2 million in 2022.
  • Biggest five-year swings in EBT: crashed 335.45% in 2021 and later surged 724.66% in 2024.
  • Year by year, EBT stood at $88.9 million in 2021, then crashed by 138.55% to -$34.3 million in 2022, then surged by 179.78% to $27.3 million in 2023, then skyrocketed by 388.98% to $133.7 million in 2024, then crashed by 35.61% to $86.1 million in 2025.
  • Business Quant data shows EBT for PTGX at $86.1 million in Q4 2025, -$39.3 million in Q3 2025, and -$34.6 million in Q2 2025.